Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Essendon, Australia Clinical Trials

A listing of Essendon, Australia clinical trials actively recruiting patients volunteers.

Found (213) clinical trials

Triple Therapy Prevention of Recurrent Intracerebral Disease EveNts Trial (TRIDENT) Cognitive Sub-Study

Cognitive decline and dementia in ICH is high due to the common underlying vasculopathy of cerebral small vessel disease (CSVD). However, in general, detailed cognitive outcomes in ICH have been neglected, possibly due to the high mortality rate of ICH (up to 60% within the first year). Blood pressure (BP) …

Phase

4.2 miles

Learn More »

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

Eligible subjects (i.e., those meeting the Inclusion / Exclusion criteria) will be enrolled in one of four cohorts based on the following criteria: Cohort 1: All eligible subjects in the PoI who are 18 year old subjects with a PIV infection and meet all of the following criteria: 1.1 Meet …

Phase

4.2 miles

Learn More »

A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON

This international, multi-center, randomized, double-blind, placebo-controlled Phase 3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with ADPKD. Patients will be randomized 1:1 to either bardoxolone methyl or placebo. Patients receiving bardoxolone methyl will start with once-daily dosing at 5 mg and will dose-escalate …

Phase

4.2 miles

Learn More »

A Study of Baricitinib (LY3009104) in Children and Adolescents With Atopic Dermatitis

The reason for this study is to see if the study drug called baricitinib works and is safe in children and teenage participants with atopic dermatitis.

Phase

4.2 miles

Learn More »

Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)

This is a randomized, multicenter, double-blind, parallel, active-control study. Approximately 300 patients aged 8 to 75 years (inclusive) will be enrolled in the study. The study will be conducted in approximately 240 study centers, globally. The investigational drug (sparsentan) is a dual-acting angiotensin receptor blocker and endothelin receptor antagonist. The …

Phase

4.2 miles

Learn More »

A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis

The purpose of this study is to evaluate the efficacy and safety of mirikizumab as maintenance therapy in participants who completed prior 12-week induction study AMAN (NCT03518086).

Phase

4.2 miles

Learn More »

Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease

The primary objective of this prospective, multicenter, double-blind, randomized, placebo-controlled, parallel group, Phase 3 study is to determine the effect of oral lucerastat monotherapy on neuropathic pain in subjects with Fabry disease (FD) through daily collection of patient-reported outcomes with an electronic diary.

Phase

4.2 miles

Learn More »

An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to, loss of response, or intolerant to conventional or biologic therapy for UC.

Phase

4.2 miles

Learn More »

Nitric Oxide During Bypass for Arterial Switch Operation

The incidence of congenital heart disease (CHD) is approximately 1/100 live born children, of which up to 50% require cardiac surgery to correct the underlying abnormality at some stage during their life. (Centre for Disease Control and Prevention, USA). Despite major improvements in CPB devices, the exposure of host blood …

Phase

4.2 miles

Learn More »

A Study to Evaluate the Safety Tolerability and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)

This study is designed 1) to describe the safety, tolerability, and immunogenicity of V114 and Prevnar 13 in pneumococcal vaccine-nave adult and pediatric recipients of allogeneic hematopoietic stem cell transplant (HSCT), and 2) to describe the safety and tolerability of PNEUMOVAX23 when administered 12 months after HSCT.

Phase

4.2 miles

Learn More »